Abstract B001: Beyond DNA damage: What truly drives anthracycline cytotoxicity?
Anthracyclines, like doxorubicin, are cornerstone therapies against pediatric sarcomas, and are a first-line treatment for virtually all osteosarcoma patients. While doxorubicin is classified as a topoisomerase II inhibitor whose antineoplastic activity is historically attributed to DNA damage, osteosarcomas are noto...